111In-DOTA-h11B6

N/A

Report date: 2025/11/24 17:27:14

Base Information

Drug Name111In-DOTA-h11B6
Drug Alias Name111-indium labelled h 11B6 - Invicro/Janssen Research & Development111In-DOTA_h11B6111In-DOTA-h11B6
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agentDiagnostic agent (In vivo) > Radionuclide Imaging agent +[5] 
Mechanisms of ActionIonising radiation emittersRadionuclide imaging enhancersKallikrein 2 inhibitors
TargetsKallikrein 2
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInvicro LlcJohnson & Johnson Innovative MedicineTomopath Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTomopath IncSpectronRXInvicro Llc +[4] 
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A